<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo> are leading causes of morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>An approach to protecting the brain during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> is to try to increase the delivery of oxygen via the residual blood flow through and around ischemic tissue </plain></SENT>
<SENT sid="2" pm="."><plain>To test this hypothesis, we used a novel oxygen delivery agent, <z:chebi fb="0" ids="16385">RSR</z:chebi>-13 (2-[4-[[(3,5-dimethylanilino)-<z:chebi fb="1" ids="23019">carbonyl</z:chebi>]-<z:chebi fb="36" ids="29309">methyl</z:chebi>]phenoxy]-2-methylpr opionic acid) </plain></SENT>
<SENT sid="3" pm="."><plain>Intravenous administration of <z:chebi fb="0" ids="16385">RSR</z:chebi>-13 increases oxygen delivery through allosteric modification of the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> molecule, resulting in a shift in the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>/oxygen dissociation curve in favour of oxygen delivery </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We studied <z:chebi fb="0" ids="16385">RSR</z:chebi>-13 in a feline model of permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> to assess its effects on cerebral oxygenation and <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="5" pm="."><plain>A randomized, blinded study of <z:chebi fb="0" ids="16385">RSR</z:chebi>-13 (n = 6) versus 0.45% saline (n = 12) was conducted, after an <z:chebi fb="0" ids="16385">RSR</z:chebi>-13 dose-escalation study (n = 4) </plain></SENT>
<SENT sid="6" pm="."><plain>Drug was administered as a preocclusion bolus followed by a continuous infusion for the duration of the experiment (5 hours) </plain></SENT>
<SENT sid="7" pm="."><plain>Brain oxygen was measured continuously with the use of a Clark oxygen electrode </plain></SENT>
<SENT sid="8" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size was measured at 5 hours after occlusion with computer-assisted volumetric analysis </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: The drug treatment group had consistently higher mean brain oxygen tension than controls (33 +/- 5 and 27 +/- 6 mm Hg, respectively) and significantly smaller <z:mpath ids='MPATH_124'>infarcts</z:mpath> (21 +/- 9% versus 33 +/- 9%, respectively, P &lt; .008) </plain></SENT>
<SENT sid="10" pm="."><plain>We observed an inverse relationship between the dose response of <z:chebi fb="0" ids="16385">RSR</z:chebi>-13 (the shift in the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>/oxygen dissociation curve) and <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These results are evidence that allosteric <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> modification is protective to the brain after <z:hpo ids='HP_0011009'>acute</z:hpo> focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, providing a new opportunity for neuroprotection and raising the possibility of enhancing the protective effect of thrombolysis and ion channel blockade </plain></SENT>
</text></document>